Noxopharm Ltd
NOX
Company Profile
Business description
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.
Contact
60 Linksley Ave
GlenhavenNSW2156
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
17
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
With increased AI spending and hopes of future data center expansion, here’s what we think of Nvidia stock.
stocks
Is this overpriced ASX share too much of a gamble?
We raise our fair value after strong results but shares are pricey.
stocks
ASX players that might thrive under a Trump administration
Recent election results have sent US markets into a record-high rally however implications remain mixed for the Australian share market. See our top ASX picks that could do better under a second Trump administration.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,539.00 | 59.10 | 0.70% |
| CAC 40 | 7,269.63 | 42.17 | -0.58% |
| DAX 40 | 19,210.81 | 52.89 | -0.27% |
| Dow JONES (US) | 43,444.99 | 305.87 | -0.70% |
| FTSE 100 | 8,063.61 | 7.58 | -0.09% |
| HKSE | 19,426.34 | 9.47 | -0.05% |
| NASDAQ | 18,680.12 | 427.53 | -2.24% |
| Nikkei 225 | 38,642.91 | 107.21 | 0.28% |
| NZX 50 Index | 12,684.88 | 8.06 | -0.06% |
| S&P 500 | 5,870.62 | 78.55 | -1.32% |
| S&P/ASX 200 | 8,285.20 | 61.20 | 0.74% |
| SSE Composite Index | 3,330.73 | 49.11 | -1.45% |